For clinical purposes, it is generally suffi cient to know that an STEC is present because management of an individual case is seldom dependent on additional subtyping. An unfortunate consequence of the increasing use of nonculture diagnostic tests for AGE is that they do not provide isolates for additional testing by public health laboratories. Public health has traditionally relied upon cultured organisms for further characterization, including subtyping for epidemiologic purposes. For this reason, in 2009 the Centers for Disease Control and Prevention published guidelines for the diagnosis of STEC by clinical laboratories (3). These guidelines recommend simultaneous culture for STEC O157 and for detection of Shiga toxin and forwarding of isolates or Shiga toxin-positive broths to public health laboratories for further characterization.
The study by M'ikanatha et al. also examined laboratory practices regarding identifi cation of Campylobacter spp. (2) . In their study, use of nonculture diagnostic tests was substantial: in 17% of laboratories that used commercial fecal antigen tests for detecting Campylobacter spp.; all but one used only the antigen assay. As with STEC, such practices result in no isolates being available for additional testing by public health laboratories. For Campylobacter spp., this approach may be of somewhat less concern because in many states this pathogen is not reportable, molecular subtyping is not routinely performed, and outbreaks are relatively rare. However, it is emblematic of the overall trend away from culturing in commercial laboratories.
With the inexorable shift away from traditional laboratory methods in the clinical world, public health laboratories will increasingly face the challenge of having to develop the capacity to routinely isolate, characterize, and subtype pathogens from clinical specimens to gather the information on which epidemiologists have become so dependent. For example, if clinical laboratories diagnose STEC without culture results, outbreak detection will be more diffi cult. Molecular subtyping is now relied on heavily to identify small clusters of potentially related infections before the number of cases is epidemiologically evident. In many respects, loss of this resource would be a step 2 decades backward to the pre-pulsed-fi eld gel electrophoresis era. In addition, implementation of nonculture diagnostic methods introduces a bias in surveillance of AGE. For example, public health surveillance for STEC has traditionally focused on E. coli O157, and culture confi rmation is still required for counting these cases in national data (4) . In 2000, non-O157 STEC became nationally reportable, but numbers remained low until toxin testing became widely available. The recent rapid increase in reported non-O157 STEC is not unique to the studies reported in this issue (5-7), and as those cases have increased, the number of reported E. coli O157 cases has decreased. It is likely that a substantial proportion of STECs identifi ed only by antigen testing are O157 (50% in 1 study) (5) . Therefore, it is necessary to take changing diagnostic methods into account if trends in AGE are to be assessed accurately.
The sensitivity, specifi city, and associated positive and negative predictive values of antigen tests for enteric pathogens also differ from those of culture, which makes it diffi cult to include the results of such tests as part of the defi nition of reportable diseases. Although such concerns are valid, policies must be developed that take into account changes in laboratory practices when evaluating trends in these pathogens. Scientifi c rigor is needed, but one must remember that clinicians respond to test results that they receive, and they trust that commercially performed tests are reliable. Regardless of how accurate is the testing method, the patient is being notifi ed and treated on the basis of these test results, and public health offi cials must respond promptly on the basis of the information available. Although it is reasonable to keep data on cases of diseases diagnosed by using culture and nonculture methods separate, these data should be monitored so as not to lose essential information regarding the incidence of these diseases.
The repertoire of methods and targets for fecal testing is rapidly expanding. Molecular diagnostics are increasing; improvements include multiplex and quantitative PCR, fl uorescence in situ hybridization, and metagenomic analyses (8) (9) (10) . It is likely that many isolate-based methods for serotyping, pulsed-fi eld gel electrophoresis, and antimicrobial drug testing will need to transition to sequence-based techniques to remain epidemiologically useful.
If these challenges are to be overcome, several issues must be addressed. Decisions about implementation of new methods in clinical laboratories are often based mostly on cost and ease of use, whereas parameters such as their sensitivity, specifi city, and relevance to public health surveillance are less likely to be emphasized. However, all these aspects should be considered carefully before new diagnostic methods are implemented in clinical laboratories. If this does not happen, surveillance for foodborne AGE is likely to become unreliable and unsuitable for guiding public health actions in the future.
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